Primary pulmonary hypertension

Friday, 12 April 2002

Organizer

 M. Leeman (Brussels, Belgium)  

Sponsors

 Actelion Switzerland
Aventis France
GlaxoSmithKline Belgium
Therabel Belgium		  

Primary pulmonary hypertension: from bench to bedside

Session I

  
Abstract no
Chair M. Leeman (Brussels, Belgium)  
9.30 – 10.10 Genetic aspects
S. Adnot (Paris, France)		  
10.10 – 10.50 Epidemiological aspects
G. Simonneau (Paris, France)		  
10.50 end of session I  
10.50 – 11.15 coffee break  

Session II

    
Chair M. Leeman (Brussels, Belgium)  
11.15 – 11.55 Medical therapeutic aspects
W. Seeger (Giessen, Germany)		  
11.55 – 12.05 Alprostadil and NO immediately after lung transplantation: effects on pulmonary vasculature 
D. Pranger, P. Bulpa, J. Jamart, E. Installé and P. Evrard (Yvoir, Belgium)
142
12.05 – 12.15 Endogenous nitric oxide opposes the pulmonary vasoconstricting effect of endothelins in vivo
I. Hubloue, D. Biarent, G. Bejjani, F. Kerbaul, R. Naeije, and M. Leeman (Brussels, Belgium)
143
12.15 – 12.25 Haemodynamic comparison of Urapidil with other therapies for primary pulmonary hypertension
Y. Laurent, P. Bulpa, J. Jamart, S. Casel, E. Installé, and P. Evrard (Yvoir, Belgium)
144
12.25 – 12.35 Transition from intravenous epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension
S. Huez, J.L. Vachiéry, and R. Naeije (Brussels, Belgium)		  
12.35 – 12.45 Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension
Y. Laurent, P. Bulpa, P. Binamé, H. Rahir, E. Installé, and P. Evrard (Yvoir, Belgium)
145
12.45 – 12.55 Effect of nitric oxide synthase-gene transfer on endothelial function of isolated rat pulmonary artery rings
L. Jiang, M. Cauberghs, P. Pokreisz, S. Janssens, M. Demedts, and M. Delcroix (Leuven, Belgium)
146
12.55 end of workshop 15